SPIKEVAX DIN 02568365
Status: Approved
Holder: MODERNA BIOPHARMA CANADA CORPORATION
Health Canada record
| Active ingredient(s) | *SARSCOV2 S-PROTEIN MRNA, 5'(M7G-5'-PPP-5'-GM), 3'POLYA 25 MCG |
|---|---|
| Dosage form | Dispersion |
| Route | Intramuscular |
| Schedule | SCHEDULE D |
| Class | Human |
| ATC | J07BN01 COVID-19, RNA-BASED VACCINE |
| Original market date | |
| Current status date | 18-May-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Moderna Biopharma Canada Corporation — licence 3-002801, currently licensed, last inspection rating C (2024-06-10).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing *SARSCOV2 S-PROTEIN MRNA, 5'(M7G-5'-PPP-5'-GM), 3'POLYA
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02541270 | SPIKEVAX | MODERNA BIOPHARMA CANADA CORPORATION | Dispersion | *SARSCOV2 S-PROTEIN MRNA, 5'(M7G-5'-PPP-5'-GM), 3'POLYA 0.1 MG | Marketed |
| 02557770 | SPIKEVAX | MODERNA BIOPHARMA CANADA CORPORATION | Dispersion | *SARSCOV2 S-PROTEIN MRNA, 5'(M7G-5'-PPP-5'-GM), 3'POLYA 50 MCG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 37581 | 2026-05-18 | Supplement to a New Drug Submission (SNDS) | New pre-filled syringe presentation. New drug product manufacturing site |